Skip to content
CancerIndex

Country

United States

Cancer incidence and mortality for United States as published by the source registry: per site group, per year and sex, with age-standardized rates where the source provides them. Population statistics describe groups, never individuals.

ISO 3166-1
USA · US
WHO region
WHO Region of the Americas
Population
not seeded — CancerIndex shows only rates and counts published by the source
Years covered
1999–2024
Cancer entities
36
Estimate types
observed

Summary

2024 · both sexes · all ages

Totals across all cancer sites are shown only when the source publishes an all-sites row. Otherwise the per-site figures below stand on their own; CancerIndex never sums site groups (definitions overlap between sources).

  • Deathshighest site group:Malignant Lung Neoplasm128,762countcdc-wonderProvenance
    Source
    CDC WONDER — Underlying Cause of Death (US mortality by ICD-10 site)
    Dataset
    CDC WONDER Underlying Cause of Death, 2018-2024, Single Race
    Version
    D158 vintage 2024
    Retrieved
    Sep 8, 2026
    Layer
    normalized (units and labels harmonized; values unchanged)
    Evidence
    registry
    License
    US Government work (public domain) subject to CDC WONDER data use restrictions (statistical reporting only; counts ≤ 9 must not be published; no re-identification)
    Run
    ING-CDCWONDER-20260908-000001
    Open at source     Observed36 site groups
  • New caseshighest site group (2023, latest available):Malignant Breast Neoplasm291,057countcdc-uscsProvenance
    Source
    U.S. Cancer Statistics (USCS) — NPCR/SEER incidence and NVSS mortality
    Dataset
    U.S. Cancer Statistics — Data Visualizations tool data tables (BYSITE.TXT)
    Version
    USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
    Retrieved
    Sep 8, 2026
    Layer
    normalized (units and labels harmonized; values unchanged)
    Evidence
    registry
    License
    US Government work (public domain); citation requested; statistical reporting and analysis only; no linkage for re-identification
    Run
    ING-CDCUSCS-20260908-000001
    Open at source     Observed32 site groups
  • Mortality rate (age-standardized)highest site group:Malignant Lung Neoplasm28per 100,000cdc-wonderProvenance
    Source
    CDC WONDER — Underlying Cause of Death (US mortality by ICD-10 site)
    Dataset
    CDC WONDER Underlying Cause of Death, 2018-2024, Single Race
    Version
    D158 vintage 2024
    Retrieved
    Sep 8, 2026
    Layer
    normalized (units and labels harmonized; values unchanged)
    Evidence
    registry
    License
    US Government work (public domain) subject to CDC WONDER data use restrictions (statistical reporting only; counts ≤ 9 must not be published; no re-identification)
    Run
    ING-CDCWONDER-20260908-000001
    Open at source     Observed36 site groups
  • Incidence rate (age-standardized)highest site group (2023, latest available):Malignant Breast Neoplasm71.3per 100,000cdc-uscsProvenance
    Source
    U.S. Cancer Statistics (USCS) — NPCR/SEER incidence and NVSS mortality
    Dataset
    U.S. Cancer Statistics — Data Visualizations tool data tables (BYSITE.TXT)
    Version
    USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
    Retrieved
    Sep 8, 2026
    Layer
    normalized (units and labels harmonized; values unchanged)
    Evidence
    registry
    License
    US Government work (public domain); citation requested; statistical reporting and analysis only; no linkage for re-identification
    Run
    ING-CDCUSCS-20260908-000001
    Open at source     Observed24 site groups

No all-sites total in source for this scope — per-site figures below; no national total is computed.

Top cancers

By deaths

2024 · both sexes · all ages · 36 site groups

#CancerDeaths (count)95% CITypeRank in scopeSite definitionSource
1Malignant Lung NeoplasmCancer128,762—observed#1 of 31C33-C34cdc-wonderObserved
2Malignant Pancreatic NeoplasmCancer51,327—observed#2 of 31C25cdc-wonderObserved
3Malignant Breast NeoplasmCancer Family43,897—observed#3 of 31C50cdc-wonderObserved
4Malignant Colon NeoplasmCancer41,022—observed#4 of 31USCS "Colon excluding Rectum" (ICD-10 C18, C26.0; ICD-O-3 C180-C189, C260)cdc-uscsObserved
5Malignant Prostate NeoplasmCancer34,815—observed#5 of 31C61cdc-wonderObserved
6Malignant Liver NeoplasmCancer30,532—observed#6 of 31C22cdc-wonderObserved
7LeukemiaCancer Family23,903—observed#7 of 31USCS "Leukemias" (ICD-10 C91-C95 (leukemia recodes; C90.1 plasma cell leukemia included by SEER); ICD-O-3 leukemia histologies 9733-9948 per SEER site recode)cdc-uscsObserved
8Non-Hodgkin LymphomaHematologic Malignancy19,882—observed#8 of 31C82-C85, C96cdc-wonderObserved
9Malignant Central Nervous System NeoplasmCancer18,523—observed#9 of 31C70-C72cdc-wonderObserved
10Malignant Bladder NeoplasmCancer17,396—observed#10 of 31C67cdc-wonderObserved
11Malignant Esophageal NeoplasmCancer16,274—observed#11 of 31C15cdc-wonderObserved
12Malignant Kidney NeoplasmCancer15,215—observed#12 of 31C64-C65cdc-wonderObserved
13Malignant Rectal NeoplasmCancer13,446—observed#13 of 31C19-C20cdc-wonderObserved
14Malignant Ovarian NeoplasmCancer12,654—observed#14 of 31USCS "Ovary" (ICD-10 C56; ICD-O-3 C569)cdc-uscsObserved
15Multiple MyelomaHematologic Malignancy11,967—observed#15 of 31C88, C90cdc-wonderObserved
16Malignant Gastric NeoplasmCancer11,246—observed#16 of 31C16cdc-wonderObserved
17Cutaneous MelanomaCancer8,671—observed#17 of 31USCS "Melanomas of the Skin" (ICD-10 C43; ICD-O-3 C440-C449 with histology 8720-8790)cdc-uscsObserved
18Malignant Uterine Corpus NeoplasmCancer8,608—observed#18 of 31C54cdc-wonderObserved
19Skin CarcinomaCancer5,462—observedno snapshotC44cdc-wonderObserved
20Malignant Lip and Oral Cavity NeoplasmCancer5,424—observedno snapshotC00-C06cdc-wonderObserved
21Malignant Gallbladder NeoplasmCancer4,402—observedno snapshotC23-C24cdc-wonderObserved
22Malignant Cervical NeoplasmCancer4,207—observed#19 of 31C53cdc-wonderObserved
23Malignant Laryngeal NeoplasmCancer4,095—observed#20 of 31C32cdc-wonderObserved
24Malignant Oropharyngeal NeoplasmCancer3,286—observedno snapshotC09-C10cdc-wonderObserved
25Malignant Thyroid Gland NeoplasmCancer2,229—observed#21 of 31USCS "Thyroid" (ICD-10 C73; ICD-O-3 C739)cdc-uscsObserved
26Malignant MesotheliomaCancer Family2,114—observed#22 of 31C45cdc-wonderObserved
27Malignant Anal NeoplasmCancer1,651—observed#23 of 31C21cdc-wonderObserved
28Malignant Vulvar NeoplasmCancer1,555—observed#24 of 31C51cdc-wonderObserved
29Malignant Salivary Gland NeoplasmCancer1,173—observed#25 of 31USCS "Salivary Gland" (ICD-10 C07-C08; ICD-O-3 C079-C089)cdc-uscsObserved
30Hodgkin LymphomaHematologic Malignancy909—observed#26 of 31C81cdc-wonderObserved
31Malignant Nasopharyngeal NeoplasmCancer664—observed#27 of 31USCS "Nasopharynx" (ICD-10 C11; ICD-O-3 C110-C119)cdc-uscsObserved
32Malignant Hypopharyngeal NeoplasmCancer498—observed#28 of 31C12-C13cdc-wonderObserved
33Malignant Testicular NeoplasmCancer462—observed#29 of 31C62cdc-wonderObserved
34Malignant Vaginal NeoplasmCancer435—observed#30 of 31C52cdc-wonderObserved
35Malignant Penile NeoplasmCancer415—observed#31 of 31C60cdc-wonderObserved
36Kaposi SarcomaCancer56—observedno snapshotC46cdc-wonderObserved
cdc-wonderProvenance
Source
CDC WONDER — Underlying Cause of Death (US mortality by ICD-10 site)
Dataset
CDC WONDER Underlying Cause of Death, 2018-2024, Single Race
Version
D158 vintage 2024
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
registry
License
US Government work (public domain) subject to CDC WONDER data use restrictions (statistical reporting only; counts ≤ 9 must not be published; no re-identification)
Run
ING-CDCWONDER-20260908-000001
Open at source Rank from snapshot geo=USA|sex=all|age=all|year=2024|level=top · full ranking and "Why this rank?"High confidencetrend ↓

Data updated 21 days agoSource updated D158 vintage 2024

Top cancers

By new cases

2023 — latest year available for this metric (2024 not yet published by the source) · both sexes · all ages · 32 site groups

#CancerNew cases (count)95% CITypeRank in scopeSite definitionSource
1Malignant Breast NeoplasmCancer Family291,057—observed#1 of 32USCS "Male and Female Breast" (ICD-10 C50; ICD-O-3 C500-C509)cdc-uscsObserved
2Malignant Prostate NeoplasmCancer266,307—observed#2 of 32USCS "Prostate" (ICD-10 C61; ICD-O-3 C619)cdc-uscsObserved
3Malignant Lung NeoplasmCancer228,058—observed#3 of 32USCS "Lung and Bronchus" (ICD-10 C34; ICD-O-3 C340-C349)cdc-uscsObserved
4Malignant Colon NeoplasmCancer108,402—observed#4 of 32USCS "Colon excluding Rectum" (ICD-10 C18, C26.0; ICD-O-3 C180-C189, C260)cdc-uscsObserved
5Cutaneous MelanomaCancer103,681—observed#5 of 32USCS "Melanomas of the Skin" (ICD-10 C43; ICD-O-3 C440-C449 with histology 8720-8790)cdc-uscsObserved
6Malignant Bladder NeoplasmCancer79,952—observed#6 of 32USCS "Urinary Bladder" (ICD-10 C67; ICD-O-3 C670-C679)cdc-uscsObserved
7Malignant Kidney NeoplasmCancer77,334—observed#7 of 32USCS "Kidney and Renal Pelvis" (ICD-10 C64-C65; ICD-O-3 C649, C659)cdc-uscsObserved
8Non-Hodgkin LymphomaHematologic Malignancy75,946—observed#8 of 32USCS "Non-Hodgkin Lymphoma" (ICD-10 C82-C85, C96.3; ICD-O-3 histology 9590-9597, 9670-9729, 9735, 9737-9738 (+9811-9818, 9823, 9827, 9837 outside marrow/blood))cdc-uscsObserved
9Malignant Uterine Corpus NeoplasmCancer62,434—observed#9 of 32USCS "Corpus" (ICD-10 C54; ICD-O-3 C540-C549)cdc-uscsObserved
10Malignant Pancreatic NeoplasmCancer61,467—observed#10 of 32USCS "Pancreas" (ICD-10 C25; ICD-O-3 C250-C259)cdc-uscsObserved
11LeukemiaCancer Family58,254—observed#11 of 32USCS "Leukemias" (ICD-10 C91-C95 (leukemia recodes; C90.1 plasma cell leukemia included by SEER); ICD-O-3 leukemia histologies 9733-9948 per SEER site recode)cdc-uscsObserved
12Malignant Thyroid Gland NeoplasmCancer49,685—observed#12 of 32USCS "Thyroid" (ICD-10 C73; ICD-O-3 C739)cdc-uscsObserved
13Malignant Rectal NeoplasmCancer47,260—observed#13 of 32USCS "Rectum and Rectosigmoid Junction" (ICD-10 C19-C20; ICD-O-3 C199, C209)cdc-uscsObserved
14Malignant Liver NeoplasmCancer39,061—observed#14 of 32USCS "Liver and Intrahepatic Bile Duct" (ICD-10 C22; ICD-O-3 C220-C221)cdc-uscsObserved
15Multiple MyelomaHematologic Malignancy32,131—observed#15 of 32USCS "Myeloma" (ICD-10 C90.0, C90.2; ICD-O-3 histology 9731-9732, 9734)cdc-uscsObserved
16Malignant Gastric NeoplasmCancer29,580—observed#16 of 32USCS "Stomach" (ICD-10 C16; ICD-O-3 C160-C169)cdc-uscsObserved
17Malignant Central Nervous System NeoplasmCancer22,882—observed#17 of 32USCS "Brain and Other Nervous System" (ICD-10 C70, C71, C72; ICD-O-3 C700-C709, C710-C719, C720-C729)cdc-uscsObserved
18Malignant Ovarian NeoplasmCancer21,112—observed#18 of 32USCS "Ovary" (ICD-10 C56; ICD-O-3 C569)cdc-uscsObserved
19Malignant Esophageal NeoplasmCancer20,036—observed#19 of 32USCS "Esophagus" (ICD-10 C15; ICD-O-3 C150-C159)cdc-uscsObserved
20Malignant Cervical NeoplasmCancer13,222—observed#20 of 32USCS "Cervix" (ICD-10 C53; ICD-O-3 C530-C539)cdc-uscsObserved
21Malignant Laryngeal NeoplasmCancer11,881—observed#21 of 32USCS "Larynx" (ICD-10 C32; ICD-O-3 C320-C329)cdc-uscsObserved
22Malignant Testicular NeoplasmCancer9,572—observed#22 of 32USCS "Testis" (ICD-10 C62; ICD-O-3 C620-C629)cdc-uscsObserved
23Malignant Anal NeoplasmCancer9,334—observed#23 of 32USCS "Anus, Anal Canal and Anorectum" (ICD-10 C21; ICD-O-3 C210-C212, C218)cdc-uscsObserved
24Hodgkin LymphomaHematologic Malignancy8,858—observed#24 of 32USCS "Hodgkin Lymphoma" (ICD-10 C81; ICD-O-3 histology 9650-9667 (nodal and extranodal))cdc-uscsObserved
25Malignant Vulvar NeoplasmCancer6,103—observed#25 of 32USCS "Vulva" (ICD-10 C51; ICD-O-3 C510-C519)cdc-uscsObserved
26Malignant Salivary Gland NeoplasmCancer5,269—observed#26 of 32USCS "Salivary Gland" (ICD-10 C07-C08; ICD-O-3 C079-C089)cdc-uscsObserved
27Malignant MesotheliomaCancer Family2,709—observed#27 of 32USCS "Mesothelioma" (ICD-10 C45; ICD-O-3 histology 9050-9055 (any site))cdc-uscsObserved
28Malignant Hypopharyngeal NeoplasmCancer2,083—observed#28 of 32USCS "Hypopharynx" (ICD-10 C12-C13; ICD-O-3 C129, C130-C139)cdc-uscsObserved
29Malignant Nasopharyngeal NeoplasmCancer1,841—observed#29 of 32USCS "Nasopharynx" (ICD-10 C11; ICD-O-3 C110-C119)cdc-uscsObserved
30Malignant Penile NeoplasmCancer1,599—observed#30 of 32USCS "Penis" (ICD-10 C60; ICD-O-3 C600-C609)cdc-uscsObserved
31Malignant Vaginal NeoplasmCancer1,382—observed#31 of 32USCS "Vagina" (ICD-10 C52; ICD-O-3 C529)cdc-uscsObserved
32Kaposi SarcomaCancer1,088—observed#32 of 32USCS "Kaposi Sarcoma" (ICD-10 C46; ICD-O-3 histology 9140 (any site))cdc-uscsObserved
cdc-uscsProvenance
Source
U.S. Cancer Statistics (USCS) — NPCR/SEER incidence and NVSS mortality
Dataset
U.S. Cancer Statistics — Data Visualizations tool data tables (BYSITE.TXT)
Version
USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
registry
License
US Government work (public domain); citation requested; statistical reporting and analysis only; no linkage for re-identification
Run
ING-CDCUSCS-20260908-000001
Open at source Rank from snapshot geo=USA|sex=all|age=all|year=2023|level=top · full ranking and "Why this rank?"High confidencetrend ↓

Data updated 22 days agoSource updated USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)

Top cancers

By mortality rate (age-standardized)

2024 · both sexes · all ages · 36 site groups · 2000 U.S. Std. Population

#CancerMortality rate (age-standardized) (per 100,000)95% CITypeRank in scopeSite definitionSource
1Malignant Lung NeoplasmCancer2827.9–28.2observed#1 of 23C33-C34cdc-wonderObserved
2Malignant Pancreatic NeoplasmCancer11.311.2–11.4observed#2 of 23USCS "Pancreas" (ICD-10 C25; ICD-O-3 C250-C259)cdc-uscsObserved
3Malignant Breast NeoplasmCancer Family10.210.1–10.3observed#3 of 23C50cdc-wonderObserved
4Malignant Colon NeoplasmCancer9.59.4–9.6observed#4 of 23USCS "Colon excluding Rectum" (ICD-10 C18, C26.0; ICD-O-3 C180-C189, C260)cdc-uscsObserved
5Malignant Prostate NeoplasmCancer7.87.7–7.9observedno snapshotC61cdc-wonderObserved
6Malignant Liver NeoplasmCancer6.76.6–6.7observed#5 of 23C22cdc-wonderObserved
7LeukemiaCancer Family5.55.5–5.6observed#6 of 23USCS "Leukemias" (ICD-10 C91-C95 (leukemia recodes; C90.1 plasma cell leukemia included by SEER); ICD-O-3 leukemia histologies 9733-9948 per SEER site recode)cdc-uscsObserved
8Non-Hodgkin LymphomaHematologic Malignancy4.54.4–4.6observed#7 of 23C82-C85, C96cdc-wonderObserved
9Malignant Central Nervous System NeoplasmCancer4.44.3–4.4observed#8 of 23C70-C72cdc-wonderObserved
10Malignant Bladder NeoplasmCancer3.93.9–4observed#9 of 23C67cdc-wonderObserved
11Malignant Esophageal NeoplasmCancer3.63.5–3.7observed#10 of 23C15cdc-wonderObserved
12Malignant Kidney NeoplasmCancer3.43.4–3.5observed#11 of 23C64-C65cdc-wonderObserved
13Malignant Rectal NeoplasmCancer3.13.1–3.2observed#12 of 23USCS "Rectum and Rectosigmoid Junction" (ICD-10 C19-C20; ICD-O-3 C199, C209)cdc-uscsObserved
14Malignant Ovarian NeoplasmCancer2.92.8–2.9observedno snapshotC56cdc-wonderObserved
15Multiple MyelomaHematologic Malignancy2.72.6–2.7observed#13 of 23C88, C90cdc-wonderObserved
16Malignant Gastric NeoplasmCancer2.62.5–2.6observed#13 of 23USCS "Stomach" (ICD-10 C16; ICD-O-3 C160-C169)cdc-uscsObserved
17Cutaneous MelanomaCancer22–2observed#15 of 23USCS "Melanomas of the Skin" (ICD-10 C43; ICD-O-3 C440-C449 with histology 8720-8790)cdc-uscsObserved
18Malignant Uterine Corpus NeoplasmCancer1.91.8–1.9observedno snapshotC54cdc-wonderObserved
19Malignant Lip and Oral Cavity NeoplasmCancer1.21.2–1.2observedno snapshotC00-C06cdc-wonderObserved
20Skin CarcinomaCancer1.21.2–1.3observedno snapshotC44cdc-wonderObserved
21Malignant Cervical NeoplasmCancer1.11–1.1observedno snapshotC53cdc-wonderObserved
22Malignant Gallbladder NeoplasmCancer10.9–1observedno snapshotC23-C24cdc-wonderObserved
23Malignant Laryngeal NeoplasmCancer0.90.9–0.9observed#16 of 23C32cdc-wonderObserved
24Malignant Oropharyngeal NeoplasmCancer0.70.7–0.7observedno snapshotC09-C10cdc-wonderObserved
25Malignant MesotheliomaCancer Family0.50.5–0.5observed#17 of 23C45cdc-wonderObserved
26Malignant Thyroid Gland NeoplasmCancer0.50.5–0.5observed#17 of 23USCS "Thyroid" (ICD-10 C73; ICD-O-3 C739)cdc-uscsObserved
27Malignant Anal NeoplasmCancer0.40.4–0.4observed#19 of 23USCS "Anus, Anal Canal and Anorectum" (ICD-10 C21; ICD-O-3 C210-C212, C218)cdc-uscsObserved
28Malignant Vulvar NeoplasmCancer0.40.3–0.4observedno snapshotC51cdc-wonderObserved
29Malignant Salivary Gland NeoplasmCancer0.30.3–0.3observed#20 of 23USCS "Salivary Gland" (ICD-10 C07-C08; ICD-O-3 C079-C089)cdc-uscsObserved
30Hodgkin LymphomaHematologic Malignancy0.20.2–0.2observed#21 of 23C81cdc-wonderObserved
31Malignant Nasopharyngeal NeoplasmCancer0.20.1–0.2observed#21 of 23USCS "Nasopharynx" (ICD-10 C11; ICD-O-3 C110-C119)cdc-uscsObserved
32Malignant Hypopharyngeal NeoplasmCancer0.10.1–0.1observed#23 of 23USCS "Hypopharynx" (ICD-10 C12-C13; ICD-O-3 C129, C130-C139)cdc-uscsObserved
33Malignant Penile NeoplasmCancer0.10.1–0.1observedno snapshotC60cdc-wonderObserved
34Malignant Testicular NeoplasmCancer0.10.1–0.1observedno snapshotC62cdc-wonderObserved
35Malignant Vaginal NeoplasmCancer0.10.1–0.1observedno snapshotC52cdc-wonderObserved
36Kaposi SarcomaCancer00–0observedno snapshotC46cdc-wonderObserved
cdc-wonderProvenance
Source
CDC WONDER — Underlying Cause of Death (US mortality by ICD-10 site)
Dataset
CDC WONDER Underlying Cause of Death, 2018-2024, Single Race
Version
D158 vintage 2024
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
registry
License
US Government work (public domain) subject to CDC WONDER data use restrictions (statistical reporting only; counts ≤ 9 must not be published; no re-identification)
Run
ING-CDCWONDER-20260908-000001
Open at source Rank from snapshot geo=USA|sex=all|age=all|year=2024|level=top · full ranking and "Why this rank?"High confidencetrend ↓

Data updated 21 days agoSource updated D158 vintage 2024

Top cancers

By incidence rate (age-standardized)

2023 — latest year available for this metric (2024 not yet published by the source) · both sexes · all ages · 24 site groups · 2000 U.S. standard population (19 age groups)

#CancerIncidence rate (age-standardized) (per 100,000)95% CITypeRank in scopeSite definitionSource
1Malignant Breast NeoplasmCancer Family71.371–71.5observed#1 of 24USCS "Male and Female Breast" (ICD-10 C50; ICD-O-3 C500-C509)cdc-uscsObserved
2Malignant Lung NeoplasmCancer50.149.9–50.3observed#2 of 24USCS "Lung and Bronchus" (ICD-10 C34; ICD-O-3 C340-C349)cdc-uscsObserved
3Malignant Colon NeoplasmCancer26.126–26.3observed#3 of 24USCS "Colon excluding Rectum" (ICD-10 C18, C26.0; ICD-O-3 C180-C189, C260)cdc-uscsObserved
4Cutaneous MelanomaCancer24.924.7–25observed#4 of 24USCS "Melanomas of the Skin" (ICD-10 C43; ICD-O-3 C440-C449 with histology 8720-8790)cdc-uscsObserved
5Malignant Kidney NeoplasmCancer18.418.2–18.5observed#5 of 24USCS "Kidney and Renal Pelvis" (ICD-10 C64-C65; ICD-O-3 C649, C659)cdc-uscsObserved
6Malignant Bladder NeoplasmCancer1817.9–18.2observed#6 of 24USCS "Urinary Bladder" (ICD-10 C67; ICD-O-3 C670-C679)cdc-uscsObserved
7Non-Hodgkin LymphomaHematologic Malignancy1817.9–18.2observed#6 of 24USCS "Non-Hodgkin Lymphoma" (ICD-10 C82-C85, C96.3; ICD-O-3 histology 9590-9597, 9670-9729, 9735, 9737-9738 (+9811-9818, 9823, 9827, 9837 outside marrow/blood))cdc-uscsObserved
8LeukemiaCancer Family14.214.1–14.3observed#8 of 24USCS "Leukemias" (ICD-10 C91-C95 (leukemia recodes; C90.1 plasma cell leukemia included by SEER); ICD-O-3 leukemia histologies 9733-9948 per SEER site recode)cdc-uscsObserved
9Malignant Pancreatic NeoplasmCancer13.913.8–14.1observed#9 of 24USCS "Pancreas" (ICD-10 C25; ICD-O-3 C250-C259)cdc-uscsObserved
10Malignant Thyroid Gland NeoplasmCancer13.713.6–13.8observed#10 of 24USCS "Thyroid" (ICD-10 C73; ICD-O-3 C739)cdc-uscsObserved
11Malignant Rectal NeoplasmCancer11.811.7–11.9observed#11 of 24USCS "Rectum and Rectosigmoid Junction" (ICD-10 C19-C20; ICD-O-3 C199, C209)cdc-uscsObserved
12Malignant Liver NeoplasmCancer8.78.6–8.7observed#12 of 24USCS "Liver and Intrahepatic Bile Duct" (ICD-10 C22; ICD-O-3 C220-C221)cdc-uscsObserved
13Multiple MyelomaHematologic Malignancy7.47.3–7.4observed#13 of 24USCS "Myeloma" (ICD-10 C90.0, C90.2; ICD-O-3 histology 9731-9732, 9734)cdc-uscsObserved
14Malignant Gastric NeoplasmCancer6.96.8–7observed#14 of 24USCS "Stomach" (ICD-10 C16; ICD-O-3 C160-C169)cdc-uscsObserved
15Malignant Central Nervous System NeoplasmCancer5.85.7–5.9observed#15 of 24USCS "Brain and Other Nervous System" (ICD-10 C70, C71, C72; ICD-O-3 C700-C709, C710-C719, C720-C729)cdc-uscsObserved
16Malignant Esophageal NeoplasmCancer4.54.4–4.6observed#16 of 24USCS "Esophagus" (ICD-10 C15; ICD-O-3 C150-C159)cdc-uscsObserved
17Malignant Laryngeal NeoplasmCancer2.62.6–2.7observed#17 of 24USCS "Larynx" (ICD-10 C32; ICD-O-3 C320-C329)cdc-uscsObserved
18Hodgkin LymphomaHematologic Malignancy2.52.5–2.6observed#18 of 24USCS "Hodgkin Lymphoma" (ICD-10 C81; ICD-O-3 histology 9650-9667 (nodal and extranodal))cdc-uscsObserved
19Malignant Anal NeoplasmCancer2.22.1–2.2observed#19 of 24USCS "Anus, Anal Canal and Anorectum" (ICD-10 C21; ICD-O-3 C210-C212, C218)cdc-uscsObserved
20Malignant Salivary Gland NeoplasmCancer1.31.3–1.3observed#20 of 24USCS "Salivary Gland" (ICD-10 C07-C08; ICD-O-3 C079-C089)cdc-uscsObserved
21Malignant MesotheliomaCancer Family0.60.6–0.7observed#21 of 24USCS "Mesothelioma" (ICD-10 C45; ICD-O-3 histology 9050-9055 (any site))cdc-uscsObserved
22Malignant Hypopharyngeal NeoplasmCancer0.50.4–0.5observed#22 of 24USCS "Hypopharynx" (ICD-10 C12-C13; ICD-O-3 C129, C130-C139)cdc-uscsObserved
23Malignant Nasopharyngeal NeoplasmCancer0.50.4–0.5observed#22 of 24USCS "Nasopharynx" (ICD-10 C11; ICD-O-3 C110-C119)cdc-uscsObserved
24Kaposi SarcomaCancer0.30.3–0.3observed#24 of 24USCS "Kaposi Sarcoma" (ICD-10 C46; ICD-O-3 histology 9140 (any site))cdc-uscsObserved
cdc-uscsProvenance
Source
U.S. Cancer Statistics (USCS) — NPCR/SEER incidence and NVSS mortality
Dataset
U.S. Cancer Statistics — Data Visualizations tool data tables (BYSITE.TXT)
Version
USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
registry
License
US Government work (public domain); citation requested; statistical reporting and analysis only; no linkage for re-identification
Run
ING-CDCUSCS-20260908-000001
Open at source Rank from snapshot geo=USA|sex=all|age=all|year=2023|level=top · full ranking and "Why this rank?"High confidencetrend ↓

Data updated 22 days agoSource updated USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)

Trend

Mortality rate (age-standardized) — top 8 cancers, all years

Top cancers of 2024 (both sexes) traced over every year published for United States. Dashed lines mark estimated or projected values; the y axis starts at zero.

Mortality rate (age-standardized) by year for the top 8 cancers in United States012.124.136.248.260.3per 100,0001999200020052010201520202024Malignant Lung Neoplasm — 1999: 55.4Malignant Lung Neoplasm — 2000: 55.8Malignant Lung Neoplasm — 2001: 55.3Malignant Lung Neoplasm — 2002: 55Malignant Lung Neoplasm — 2003: 54.2Malignant Lung Neoplasm — 2004: 53.4Malignant Lung Neoplasm — 2005: 52.9Malignant Lung Neoplasm — 2006: 51.7Malignant Lung Neoplasm — 2007: 50.7Malignant Lung Neoplasm — 2008: 49.6Malignant Lung Neoplasm — 2009: 48.4Malignant Lung Neoplasm — 2010: 47.4Malignant Lung Neoplasm — 2011: 46.1Malignant Lung Neoplasm — 2012: 45.2Malignant Lung Neoplasm — 2013: 43.8Malignant Lung Neoplasm — 2014: 42.6Malignant Lung Neoplasm — 2015: 41.2Malignant Lung Neoplasm — 2016: 39.1Malignant Lung Neoplasm — 2017: 37.3Malignant Lung Neoplasm — 2018: 34.8Malignant Lung Neoplasm — 2018: 34.8Malignant Lung Neoplasm — 2019: 33.4Malignant Lung Neoplasm — 2019: 33.4Malignant Lung Neoplasm — 2020: 31.9Malignant Lung Neoplasm — 2020: 32.5Malignant Lung Neoplasm — 2021: 31.5Malignant Lung Neoplasm — 2021: 31.7Malignant Lung Neoplasm — 2022: 30.2Malignant Lung Neoplasm — 2022: 30.1Malignant Lung Neoplasm — 2023: 29.5Malignant Lung Neoplasm — 2023: 29.3Malignant Lung Neoplasm — 2024: 27.9Malignant Lung Neoplasm — 2024: 28Malignant Pancreatic Neoplasm — 1999: 10.6Malignant Pancreatic Neoplasm — 2000: 10.5Malignant Pancreatic Neoplasm — 2001: 10.6Malignant Pancreatic Neoplasm — 2002: 10.6Malignant Pancreatic Neoplasm — 2003: 10.5Malignant Pancreatic Neoplasm — 2004: 10.7Malignant Pancreatic Neoplasm — 2005: 10.8Malignant Pancreatic Neoplasm — 2006: 10.9Malignant Pancreatic Neoplasm — 2007: 10.8Malignant Pancreatic Neoplasm — 2008: 11Malignant Pancreatic Neoplasm — 2009: 10.8Malignant Pancreatic Neoplasm — 2010: 11Malignant Pancreatic Neoplasm — 2011: 10.9Malignant Pancreatic Neoplasm — 2012: 11.1Malignant Pancreatic Neoplasm — 2013: 10.9Malignant Pancreatic Neoplasm — 2014: 11Malignant Pancreatic Neoplasm — 2015: 11.2Malignant Pancreatic Neoplasm — 2016: 11.2Malignant Pancreatic Neoplasm — 2017: 11.3Malignant Pancreatic Neoplasm — 2018: 11Malignant Pancreatic Neoplasm — 2018: 11.1Malignant Pancreatic Neoplasm — 2019: 11Malignant Pancreatic Neoplasm — 2019: 11Malignant Pancreatic Neoplasm — 2020: 11.3Malignant Pancreatic Neoplasm — 2020: 11.1Malignant Pancreatic Neoplasm — 2021: 11.4Malignant Pancreatic Neoplasm — 2021: 11.4Malignant Pancreatic Neoplasm — 2022: 11.2Malignant Pancreatic Neoplasm — 2022: 11.1Malignant Pancreatic Neoplasm — 2023: 11.2Malignant Pancreatic Neoplasm — 2023: 11.2Malignant Pancreatic Neoplasm — 2024: 11.3Malignant Pancreatic Neoplasm — 2024: 11.3Malignant Breast Neoplasm — 1999: 15.2Malignant Breast Neoplasm — 2000: 15.2Malignant Breast Neoplasm — 2001: 14.8Malignant Breast Neoplasm — 2002: 14.5Malignant Breast Neoplasm — 2003: 14.3Malignant Breast Neoplasm — 2004: 13.8Malignant Breast Neoplasm — 2005: 13.6Malignant Breast Neoplasm — 2006: 13.2Malignant Breast Neoplasm — 2007: 12.9Malignant Breast Neoplasm — 2008: 12.7Malignant Breast Neoplasm — 2009: 12.4Malignant Breast Neoplasm — 2010: 12.3Malignant Breast Neoplasm — 2011: 12Malignant Breast Neoplasm — 2012: 11.9Malignant Breast Neoplasm — 2013: 11.6Malignant Breast Neoplasm — 2014: 11.5Malignant Breast Neoplasm — 2015: 11.4Malignant Breast Neoplasm — 2016: 11.2Malignant Breast Neoplasm — 2017: 11.2Malignant Breast Neoplasm — 2018: 10.9Malignant Breast Neoplasm — 2018: 10.9Malignant Breast Neoplasm — 2019: 10.7Malignant Breast Neoplasm — 2019: 10.7Malignant Breast Neoplasm — 2020: 10.7Malignant Breast Neoplasm — 2020: 10.5Malignant Breast Neoplasm — 2021: 10.6Malignant Breast Neoplasm — 2021: 10.6Malignant Breast Neoplasm — 2022: 10.3Malignant Breast Neoplasm — 2022: 10.4Malignant Breast Neoplasm — 2023: 10.2Malignant Breast Neoplasm — 2023: 10.2Malignant Breast Neoplasm — 2024: 10.2Malignant Breast Neoplasm — 2024: 10.2Malignant Colon Neoplasm — 1999: 17.9Malignant Colon Neoplasm — 2000: 17.6Malignant Colon Neoplasm — 2001: 17.1Malignant Colon Neoplasm — 2002: 16.8Malignant Colon Neoplasm — 2003: 16.2Malignant Colon Neoplasm — 2004: 15.2Malignant Colon Neoplasm — 2005: 14.7Malignant Colon Neoplasm — 2006: 14.4Malignant Colon Neoplasm — 2007: 14.1Malignant Colon Neoplasm — 2008: 13.6Malignant Colon Neoplasm — 2009: 13Malignant Colon Neoplasm — 2010: 12.6Malignant Colon Neoplasm — 2011: 12.4Malignant Colon Neoplasm — 2012: 12.1Malignant Colon Neoplasm — 2013: 11.9Malignant Colon Neoplasm — 2014: 11.6Malignant Colon Neoplasm — 2015: 11.5Malignant Colon Neoplasm — 2016: 11.2Malignant Colon Neoplasm — 2017: 10.9Malignant Colon Neoplasm — 2018: 10.5Malignant Colon Neoplasm — 2018: 10.4Malignant Colon Neoplasm — 2019: 10Malignant Colon Neoplasm — 2019: 10.1Malignant Colon Neoplasm — 2020: 9.8Malignant Colon Neoplasm — 2020: 10.1Malignant Colon Neoplasm — 2021: 10Malignant Colon Neoplasm — 2021: 10Malignant Colon Neoplasm — 2022: 9.6Malignant Colon Neoplasm — 2022: 9.7Malignant Colon Neoplasm — 2023: 9.6Malignant Colon Neoplasm — 2023: 9.6Malignant Colon Neoplasm — 2024: 9.5Malignant Colon Neoplasm — 2024: 9.4Malignant Prostate Neoplasm — 2018: 7.8Malignant Prostate Neoplasm — 2019: 7.7Malignant Prostate Neoplasm — 2020: 7.8Malignant Prostate Neoplasm — 2021: 8Malignant Prostate Neoplasm — 2022: 7.7Malignant Prostate Neoplasm — 2023: 7.8Malignant Prostate Neoplasm — 2024: 7.8Malignant Liver Neoplasm — 1999: 4.5Malignant Liver Neoplasm — 2000: 4.6Malignant Liver Neoplasm — 2001: 4.7Malignant Liver Neoplasm — 2002: 4.9Malignant Liver Neoplasm — 2003: 5Malignant Liver Neoplasm — 2004: 5.1Malignant Liver Neoplasm — 2005: 5.3Malignant Liver Neoplasm — 2006: 5.3Malignant Liver Neoplasm — 2007: 5.4Malignant Liver Neoplasm — 2008: 5.6Malignant Liver Neoplasm — 2009: 5.8Malignant Liver Neoplasm — 2010: 5.9Malignant Liver Neoplasm — 2011: 6.1Malignant Liver Neoplasm — 2012: 6.4Malignant Liver Neoplasm — 2013: 6.5Malignant Liver Neoplasm — 2014: 6.5Malignant Liver Neoplasm — 2015: 6.7Malignant Liver Neoplasm — 2016: 6.7Malignant Liver Neoplasm — 2017: 6.7Malignant Liver Neoplasm — 2018: 6.6Malignant Liver Neoplasm — 2018: 6.7Malignant Liver Neoplasm — 2019: 6.6Malignant Liver Neoplasm — 2019: 6.6Malignant Liver Neoplasm — 2020: 6.6Malignant Liver Neoplasm — 2020: 6.6Malignant Liver Neoplasm — 2021: 6.7Malignant Liver Neoplasm — 2021: 6.6Malignant Liver Neoplasm — 2022: 6.6Malignant Liver Neoplasm — 2022: 6.6Malignant Liver Neoplasm — 2023: 6.6Malignant Liver Neoplasm — 2023: 6.7Malignant Liver Neoplasm — 2024: 6.6Malignant Liver Neoplasm — 2024: 6.7Leukemia — 1999: 7.7Leukemia — 2000: 7.7Leukemia — 2001: 7.6Leukemia — 2002: 7.5Leukemia — 2003: 7.4Leukemia — 2004: 7.3Leukemia — 2005: 7.3Leukemia — 2006: 7.2Leukemia — 2007: 7.1Leukemia — 2008: 7.1Leukemia — 2009: 7.1Leukemia — 2010: 6.9Leukemia — 2011: 7Leukemia — 2012: 6.9Leukemia — 2013: 6.8Leukemia — 2014: 6.7Leukemia — 2015: 6.4Leukemia — 2016: 6.4Leukemia — 2017: 6.3Leukemia — 2018: 6Leukemia — 2018: 6Leukemia — 2019: 5.9Leukemia — 2019: 5.8Leukemia — 2020: 6Leukemia — 2020: 5.8Leukemia — 2021: 5.8Leukemia — 2021: 5.9Leukemia — 2022: 5.8Leukemia — 2022: 5.6Leukemia — 2023: 5.6Leukemia — 2023: 5.6Leukemia — 2024: 5.5Leukemia — 2024: 5.5Non-Hodgkin Lymphoma — 1999: 8.3Non-Hodgkin Lymphoma — 2000: 8.2Non-Hodgkin Lymphoma — 2001: 7.9Non-Hodgkin Lymphoma — 2002: 7.7Non-Hodgkin Lymphoma — 2003: 7.4Non-Hodgkin Lymphoma — 2004: 7.1Non-Hodgkin Lymphoma — 2005: 6.9Non-Hodgkin Lymphoma — 2006: 6.7Non-Hodgkin Lymphoma — 2007: 6.6Non-Hodgkin Lymphoma — 2008: 6.4Non-Hodgkin Lymphoma — 2009: 6.3Non-Hodgkin Lymphoma — 2010: 6.1Non-Hodgkin Lymphoma — 2011: 6.1Non-Hodgkin Lymphoma — 2012: 6Non-Hodgkin Lymphoma — 2013: 5.8Non-Hodgkin Lymphoma — 2014: 5.7Non-Hodgkin Lymphoma — 2015: 5.6Non-Hodgkin Lymphoma — 2016: 5.5Non-Hodgkin Lymphoma — 2017: 5.4Non-Hodgkin Lymphoma — 2018: 5.1Non-Hodgkin Lymphoma — 2018: 5.2Non-Hodgkin Lymphoma — 2019: 5Non-Hodgkin Lymphoma — 2019: 5Non-Hodgkin Lymphoma — 2020: 4.9Non-Hodgkin Lymphoma — 2020: 5Non-Hodgkin Lymphoma — 2021: 4.9Non-Hodgkin Lymphoma — 2021: 5Non-Hodgkin Lymphoma — 2022: 4.7Non-Hodgkin Lymphoma — 2022: 4.8Non-Hodgkin Lymphoma — 2023: 4.7Non-Hodgkin Lymphoma — 2023: 4.7Non-Hodgkin Lymphoma — 2024: 4.5Non-Hodgkin Lymphoma — 2024: 4.5
Malignant Lung Neoplasm28 (2024)Malignant Pancreatic Neoplasm11.3 (2024)Malignant Breast Neoplasm10.2 (2024)Malignant Colon Neoplasm9.4 (2024)Malignant Prostate Neoplasm7.8 (2024)Malignant Liver Neoplasm6.7 (2024)Leukemia5.5 (2024)Non-Hodgkin Lymphoma4.5 (2024)

cdc-uscsObservedstandard: 2000 U.S. standard population (19 age groups)238 points

Clinical research

Clinical trial activity in United States

Registrant-entered study locations on ClinicalTrials.gov mapped to this country (any study type, any phase). A site is one location; a multi-site study weighs by its number of sites. Recruiting = location status RECRUITING, or the study status when the site has none.

Trial map →
Sites
609,712
Studies with a site here
50,881
Recruiting sites
71,558
Recruiting studies
7,743
Top-level cancers by sites in United States (descendants included)
CancerSitesStudiesRecruiting studiesShare of sites
Malignant Lung Neoplasm83,3944,58273913.7%
Malignant Breast Neoplasm81,6535,55282513.4%
Leukemia51,3944,6586468.4%
Non-Hodgkin Lymphoma46,7364,3346807.7%
Malignant Prostate Neoplasm35,4943,2265435.8%
Malignant Ovarian Neoplasm28,3141,6732584.6%
Malignant Uterine Corpus Neoplasm22,5018381833.7%
Malignant Kidney Neoplasm22,2491,2131693.6%
Malignant Pancreatic Neoplasm20,3721,8113213.3%
Malignant Cervical Neoplasm19,3738301443.2%
Multiple Myeloma18,6411,8792593.1%
Malignant Central Nervous System Neoplasm18,6331,6943053.1%
Malignant Bladder Neoplasm14,6587531502.4%
Malignant Liver Neoplasm12,9021,1871932.1%
Malignant Esophageal Neoplasm11,3666711521.9%
Malignant Gastric Neoplasm10,8317001461.8%
Malignant Colon Neoplasm8,850561621.5%
Malignant Rectal Neoplasm8,089436701.3%
Cutaneous Melanoma7,096165271.2%
Hodgkin Lymphoma5,597647740.9%
Malignant Oropharyngeal Neoplasm4,994297640.8%
Skin Carcinoma4,964232520.8%
Malignant Thyroid Gland Neoplasm4,053301600.7%
Malignant Lip and Oral Cavity Neoplasm4,046228490.7%
Malignant Laryngeal Neoplasm3,710164310.6%
By phase (a Phase II/III study counts in both)
PhaseSitesStudiesRecruiting
Phase 180,05716,1002,359
Phase 2255,68419,5792,688
Phase 3247,9924,036558
Phase 43,751591100

Computed formula ci-trial-sites-v1 · source: clinicaltrials · shares are of sites, not of studies

Data updated 17 hours agoSource updated unknowntrial_site_country_counts

Regulatory

Oncology approval records · US

Records of the country's regulator as ingested (one record = one decision for one application or product identifier). Absence of a record here is not evidence of absence.

All records →

FDA · approved: 2,343 records / 304 drugs

  • Sep 18, 2026Abemaciclib approved cancer not stated in this recordEfficacy supplement 2026-09-18 (see label)openfda
  • Sep 9, 2026Aminolevulinic Acid approved cancer not stated in this recordEfficacy supplement 2026-09-09 (see label)openfda
  • Sep 9, 2026Sevabertinib approved cancer not stated in this recordEfficacy supplement 2026-09-09 (see label)openfda
  • Sep 4, 2026Camizestrant approved Malignant Breast Neoplasmin combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for the treatment of adult patients with hormone receptor…openfda
  • Aug 28, 2026Ropeginterferon Alfa-2b approved cancer not stated in this recordEfficacy supplement 2026-08-28 (see label)openfda
  • Aug 25, 2026Zanidatamab approved cancer not stated in this recordEfficacy supplement 2026-08-25 (see label)openfda
  • Aug 25, 2026Tislelizumab approved cancer not stated in this recordEfficacy supplement 2026-08-25 (see label)openfda
  • Jul 24, 2026Enzalutamide approved cancer not stated in this recordEfficacy supplement 2026-07-24 (see label)openfda
  • Jul 24, 2026Enzalutamide approved cancer not stated in this recordEfficacy supplement 2026-07-24 (see label)openfda
  • Jul 14, 2026Selpercatinib approved cancer not stated in this recordEfficacy supplement 2026-07-14 (see label)openfda

Regulatory

Provenance

Sources and freshness

What each source covers for this geography, exactly as ingested. Values are normalized (units, labels) but never changed.

SourceMetricSexYearsCancersEstimate typesStandard populationIngested
cdc-uscsIncidence rate (age-standardized)Both1999–2023 (25)24observed2000 U.S. standard population (19 age groups)2026-09-08
cdc-uscsIncidence rate (age-standardized)Female1999–2023 (25)29observed2000 U.S. standard population (19 age groups)2026-09-08
cdc-uscsIncidence rate (age-standardized)Male1999–2023 (25)27observed2000 U.S. standard population (19 age groups)2026-09-08
cdc-uscsMortality rate (age-standardized)Both1999–2024 (26)23observed2000 U.S. standard population (19 age groups)2026-09-08
cdc-wonderMortality rate (age-standardized)Both2018–2024 (7)36observed2000 U.S. Std. Population2026-09-08
cdc-uscsMortality rate (age-standardized)Female1999–2024 (26)28observed2000 U.S. standard population (19 age groups)2026-09-08
cdc-wonderMortality rate (age-standardized)Female2018–2024 (7)36observed2000 U.S. Std. Population2026-09-08
cdc-uscsMortality rate (age-standardized)Male1999–2024 (26)26observed2000 U.S. standard population (19 age groups)2026-09-08
cdc-wonderMortality rate (age-standardized)Male2018–2024 (7)36observed2000 U.S. Std. Population2026-09-08
cdc-uscsNew casesBoth1999–2023 (25)32observed—2026-09-08
cdc-uscsNew casesFemale1999–2023 (25)29observed—2026-09-08
cdc-uscsNew casesMale1999–2023 (25)27observed—2026-09-08
cdc-uscsDeathsBoth1999–2024 (26)31observed—2026-09-08
cdc-wonderDeathsBoth2018–2024 (7)36observed—2026-09-08
cdc-uscsDeathsFemale1999–2024 (26)28observed—2026-09-08
cdc-wonderDeathsFemale2018–2024 (7)36observed—2026-09-08
cdc-uscsDeathsMale1999–2024 (26)26observed—2026-09-08
cdc-wonderDeathsMale2018–2024 (7)36observed—2026-09-08
cdc-wonderMortality rate (crude)Both2018–2024 (7)36observed—2026-09-08
cdc-wonderMortality rate (crude)Female2018–2024 (7)36observed—2026-09-08
cdc-wonderMortality rate (crude)Male2018–2024 (7)36observed—2026-09-08

Age-standardized rates use the 2000 U.S. standard population (19 age groups); they are not comparable with rates standardized to the World (Segi) population used by IARC. Global comparisons are not available: the IARC Global Cancer Observatory remains under license review and the SEER API awaits credentials (CLAUDE.md §10.3-10.4). Only geographies with licensed observations get a page; see /countries.

Data updated 21 days agoSource updated 1999–202410,680 observations approx. · ranks from snapshots geo=USA